Radiation plus immunotherapy shows promise in shrinking liver tumors before surgery
NCT ID NCT04857684
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tests whether giving a short course of focused radiation along with two immunotherapy drugs (atezolizumab and bevacizumab) before surgery can safely shrink liver cancer and improve outcomes. About 20 adults with resectable liver cancer will receive this combination, then undergo surgery. The main goal is to check safety and side effects, while also measuring how well the tumors respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.